Molecular Docking & Drug Pipeline
SHP2 inhibitors vs PTPN11 E76Q, IDH2 inhibitors vs IDH2 R140Q · Boltz-2 affinity, DiffDock 2.0
Best PTPN11 Binder
RMC-4550
Boltz-2 pIC50 6.21 · DiffDock 2.0 -1.65
Best IDH2 Binder
Enasidenib
Boltz-2 pIC50 5.23 · FDA 2017
DiffDock 2.0 Top (SHP2)
SHP099
Confidence -1.53 · top of 10 poses · low band (below -1.5)
Boltz-1 Runs Ligand invalid
4/4
Vast.ai A100 · wrong SMILES, superseded 15 Apr 2026
Binding Affinity Comparison
Boltz-2 predicted pIC50 (6 minus affinity_pred_value; NVIDIA NIM,
15 Apr 2026), ligands from PubChem-verified SMILES. Higher pIC50
means tighter predicted binding; pIC50 6 corresponds to 1 µM.
AG-221 is enasidenib run a second time (same PubChem CID), so the gap
between those two bars is run-to-run noise. Hover a bar for the Boltz-2
binding probability (below 50% for all three SHP2 inhibitors) and the
DiffDock 2.0 top-pose confidence 33
[33] G 2023
DiffDock: Diffusion Steps, Twists, and Turns for Molecular Docking. ICLR (2023)
for
the same pair. Ranking for PTPN11 E76Q: Boltz-2 RMC-4550 > TNO155 > SHP099;
DiffDock 2.0 SHP099 > RMC-4550 > TNO155 (all three in DiffDock's
low-confidence band, below -1.5).
Superseded Docking Runs
The AutoDock Vina, DiffDock v1 and Boltz-1 results below were
computed against the wrong molecules. On 15 Apr 2026 a
QA pass checked every drug SMILES string against PubChem and found that
all of them were syntactically valid but encoded different compounds
(TNO155 off by +70.6 Da, RMC-4550 +47.6 Da, ivosidenib −236.3 Da).
The scores are kept here so earlier reports can be reconciled, and are
not evidence for any drug. The reruns above use the corrected SMILES.
The methods do not agree on the PTPN11 E76Q ranking: Boltz-2 puts
RMC-4550 first, DiffDock 2.0 puts SHP099 first, and
the invalid Vina run put TNO155 first.
| Target | Drug | Vina (kcal/mol) | DiffDock v1 | Status |
|---|---|---|---|---|
| PTPN11 E76Q | RMC-4550 | Invalid ligand | ||
| PTPN11 E76Q | SHP099 | Invalid ligand | ||
| PTPN11 E76Q | TNO155 | Invalid ligand | ||
| IDH2 R140Q | Enasidenib | Not run | Invalid ligand | |
| IDH2 R140Q | Ivosidenib | Not run | Invalid ligand |
AutoDock Vina 1.2.x (local, RTX 4060) 32
[32] O 2010
AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem (2010)
and DiffDock v1 NIM 33[33] G 2023
DiffDock: Diffusion Steps, Twists, and Turns for Molecular Docking. ICLR (2023)
, March 2026, with
hallucinated ligand SMILES. Struck through on purpose.
Drug Pipeline
| Drug | Target | Mechanism | Phase | Best Score | Evidence Source | Notes |
|---|---|---|---|---|---|---|
| Enasidenib 21 [21] EM 2017 Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood (2017) | IDH2 R140Q | IDH2 inhibitor | FDA Approved (2017) | pIC50 5.23 · DD2 -1.40 | OncoKB Level 1, PharmGKB Testing Required | Standard for IDH2-mutant AML |
| Vorasidenib | IDH2 | Dual IDH1/2 inhibitor | FDA (glioma 2024) / Phase I (AML) | pIC50 4.76 · DD2 -0.82 | DGIdb, ClinicalTrials.gov | AML: Phase I only (AG-881, NCT02492737, completed) |
| TNO155 23 [23] MJ 2020 Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer. J Med Chem (2020) | PTPN11 E76Q | SHP2 allosteric inhibitor | No hematological trial (Phase I/II in solid tumours) | pIC50 5.41 · DD2 -1.68 | DGIdb confirmed (as batoprotafib) | Novartis lead compound |
| RMC-4550 | PTPN11 E76Q | SHP2 allosteric inhibitor | Preclinical | pIC50 6.21 · DD2 -1.65 | Literature (FLT3/KIT-mutant AML models) 22 [22] B 2023 Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML. Cell Rep Med (2023) | Revolution Medicines |
| Trametinib | MEK (PTPN11→MAPK) | MEK inhibitor | FDA (melanoma) | Not docked | DGIdb | Convergence node for PTPN11+SETBP1 |
| SHP099 | PTPN11 E76Q | SHP2 allosteric inhibitor | Tool compound | pIC50 5.13 · DD2 -1.53 | Literature | Preclinical only |
| Venetoclax | BCL-2 | BH3 mimetic | FDA Approved (2018) | Not docked | PharmGKB | Backbone with azacitidine |
| Azacitidine | DNMT3A | Hypomethylating agent | FDA Approved | Not docked | PharmGKB, DGIdb | Standard backbone |
| FTY720 1 [1] R 2013 Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2013) | PP2A (SETBP1) | PP2A activator | Preclinical (AML) | Not docked | Literature | MS-approved drug repurposing |
Best score: Boltz-2 predicted pIC50 and DiffDock 2.0 top-pose confidence
(DD2: above 0 high, -1.5 to 0 moderate, below -1.5 low), both with
PubChem-verified SMILES (15 Apr 2026).
Phase refers to highest clinical development stage for the relevant
hematological indication. Evidence sources: DGIdb
38
[38] SL 2021
Integration of the Drug-Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts. Nucleic Acids Res (2021)
, PharmGKB
39[39] M 2021
An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine. Clin Pharmacol Ther (2021)
, OncoKB
35[35] D 2017
OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol (2017)
. The DepMap
46[46] A 2017
Defining a Cancer Dependency Map. Cell (2017)
query returned no data.
Drug Sensitivity (Literature)
The DepMap query for these genes and compounds returned no data, so no
DepMap analysis was done. Published cell-line evidence: in FLT3- and
KIT-mutant AML cell lines, the SHP2 inhibitor RMC-4550 lowered MCL1,
raised BMF and increased apoptotic dependency on BCL2, and RMC-4550 plus
venetoclax was synergistically lethal in cell lines and xenografts
22
Whether SHP2 inhibition would add to venetoclax in a PTPN11 E76Q clone is therefore an extrapolation from RTK-driven AML, not a tested result.
[22] B 2023
Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML. Cell Rep Med (2023)
. PTPN11-mutant cells were not part of
that study.
Whether SHP2 inhibition would add to venetoclax in a PTPN11 E76Q clone is therefore an extrapolation from RTK-driven AML, not a tested result.
Synthetic Lethality
| Gene Pair | Interaction Type | Evidence Level | Therapeutic Implication |
|---|---|---|---|
| DNMT3A + EZH2 | Functional association (STRING) | STRING 0.999 44 [44] D 2023 The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res (2023) | Highest STRING score of the 10 patient-gene pairs, mostly from text mining (0.998) |
| IDH2 + SETBP1 | Possible synthetic lethality (hypothesis) | Literature-curated; no SynLethDB hit | Not mutually exclusive in GENIE: 20 samples observed vs 22.0 expected (O/E 0.91) |
| PTPN11 + BCL2 | Cooperative (SHP2 + BCL2 inhibition) | Literature (FLT3/KIT-mutant AML) 22 [22] B 2023 Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML. Cell Rep Med (2023) | SHP2i + venetoclax synergy shown in RTK-driven AML, not in PTPN11-mutant cells |
| EZH2 + Mono7 | Haploinsufficiency | Literature 10 [10] A 2020 Mutational mechanisms of EZH2 inactivation in myeloid neoplasms. Leukemia (2020) 9[9] T 2010 Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet (2010) | EZH2 LoF + chr7 TSG loss compound |
Gene pair interactions relevant to this mutation profile.
Evidence from STRING, a literature-curated synthetic lethality list
(the SynLethDB API returned no usable data), GENIE co-occurrence and
published literature.
Boltz-1 Co-folding
Ligands in these four runs were wrong. The same
hallucinated SMILES strings as in the superseded Vina and DiffDock v1
runs were used, so the binding geometries described here are not valid
evidence (found 15 Apr 2026). Protein-only conclusions stand; the
Boltz-2 affinities above are the valid replacement.
4 drug-protein complexes completed via Boltz-1 34
Coverage gaps: DNMT3A R882H is not directly druggable (addressed by hypomethylating agents). SETBP1 G870S 1
4 drug-protein complexes completed via Boltz-1 34
[34] J 2024
Boltz-1: Democratizing Biomolecular Interaction Modeling. bioRxiv (2024)
on Vast.ai A100: - IDH2 R140Q + Enasidenib 21[21] EM 2017Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood (2017): ligand MW 490.5 Da, PubChem enasidenib 473.4 Da
- IDH2 R140Q + AG-221 21[21] EM 2017Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood (2017): same wrong ligand as the enasidenib run (AG-221 is enasidenib)
- PTPN11 E76Q + TNO155 23[23] MJ 2020Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer. J Med Chem (2020): ligand MW 492.5 Da, PubChem TNO155 421.9 Da
- PTPN11 E76Q + RMC-4550: ligand MW 485.0 Da, PubChem RMC-4550 437.4 Da
Coverage gaps: DNMT3A R882H is not directly druggable (addressed by hypomethylating agents). SETBP1 G870S 1
[1] R 2013
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2013)
has no known small-molecule
inhibitors; G870S raises SET and lowers PP2A activity
1[1] R 2013
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2013)
, so PP2A activation (FTY720/fingolimod)
is the closest experimental strategy.
Treatment Strategy
Recommended backbone: venetoclax + azacitidine + enasidenib
21
This combination addresses DNMT3A R882H (via hypomethylation) and the small IDH2 R140Q subclone, VAF 2% (via direct inhibition). Enasidenib 21
SHP2 inhibitors (TNO155 23
No direct SETBP1 inhibitors exist. SETBP1 G870S disrupts the SKI domain degron motif 1
[21] EM 2017
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood (2017)
This combination addresses DNMT3A R882H (via hypomethylation) and the small IDH2 R140Q subclone, VAF 2% (via direct inhibition). Enasidenib 21
[21] EM 2017
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood (2017)
is FDA-approved for relapsed/refractory IDH2-mutant AML. As a triplet it has been
given with venetoclax and oral decitabine, not azacitidine (DiNardo et al.,
J Clin Oncol 2025, PMID 40513054: 60 IDH1/IDH2-mutant patients across arms, CRc 92%).
Risk classification: ELN 2022 Adverse
14[14] H 2022
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood (2022)
.
SHP2 inhibitors (TNO155 23
[23] MJ 2020
Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer. J Med Chem (2020)
, RMC-4550): no myeloid trial.
TNO155 trials are in solid tumours only, RMC-4550 is preclinical, and the one
AML study with an allosteric SHP2 inhibitor (ERAS-601, NCT05279859) was withdrawn. PTPN11 E76Q activates
the RAS-MAPK pathway; allosteric SHP2 inhibition locks the phosphatase in its
autoinhibited state. These agents represent the most promising targeted option
for the PTPN11 subclone.
In FLT3- and KIT-mutant AML cell lines, SHP2 inhibition lowered MCL1 and
synergised with venetoclax 22[22] B 2023
Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML. Cell Rep Med (2023)
; PTPN11-mutant
cells were not tested.
No direct SETBP1 inhibitors exist. SETBP1 G870S disrupts the SKI domain degron motif 1
[1] R 2013
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2013)
, stabilizing the protein and suppressing PP2A tumor
suppressor activity via higher SET levels 1[1] R 2013
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2013)
. FTY720 (fingolimod), approved for multiple sclerosis,
reactivates PP2A and has preclinical activity in AML cell models; no study in SETBP1-mutant AML was found in PubMed.
This represents an experimental drug repurposing strategy.
CRITICAL: Tazemetostat (EZH2 inhibitor) is CONTRAINDICATED
for this patient. EZH2 V662A is predicted loss-of-function: SET-domain
missense mutations abrogate catalytic activity 10
[10] A 2020
Mutational mechanisms of EZH2 inactivation in myeloid neoplasms. Leukemia (2020)
9[9] T 2010
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet (2010)
,
but V662A itself has not been tested. Tazemetostat inhibits
EZH2 activity that is already lost. Administering an EZH2 inhibitor would provide
no therapeutic benefit and could exacerbate the epigenetic dysregulation caused by
the existing EZH2 LoF mutation.
References
- Stein EM et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood (2017). PubMed
- LaMarche MJ et al. Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer. J Med Chem (2020). DOI
- Popescu B et al. Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in AML. Cell Rep Med (2023). DOI
- Piazza R et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2013). PubMed
- Piazza R et al. SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub. Nat Commun (2018). DOI
- Chase A et al. Mutational mechanisms of EZH2 inactivation in myeloid neoplasms. Leukemia (2020). DOI
- Ernst T et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet (2010). PubMed
- Döhner H et al. Diagnosis and management of AML in adults: 2022 ELN recommendations. Blood (2022). PubMed
- Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking. J Comput Chem (2010). DOI
- Corso G et al. DiffDock: Diffusion Steps, Twists, and Turns for Molecular Docking. ICLR (2023). DOI
- Passaro S et al. Boltz-2: Towards Accurate and Efficient Binding Affinity Prediction. bioRxiv (2025). DOI
- Wohlwend J et al. Boltz-1: Democratizing Biomolecular Interaction Modeling. bioRxiv (2024). DOI